Product Images Alfuzosin Hydrochloride
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 9 images provide visual information about the product associated with Alfuzosin Hydrochloride NDC 51655-432 by Northwind Pharmaceuticals, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - 51655 432 52
This is a prescription medication with National Drug Code 51655-432-52. The medication is Alfuzosin Hydrochloride Extended-Release Tablets, which contain 10mg of active ingredient. Each bottle contains 30 tablets. The usage and dosage information is not available from the given text.*
chemical-structure - chemical structure
figure-1 - figure 1
figure-2 - figure 2
The given text appears to be a part of a scientific study report. It includes a table showing the effect of placebo and Alfuzosin hydrochloride extended-release tablets on the IPSS total symptom score in a trial of 84 days. The data shows significant reduction in symptoms in the group taking Alfuzosin hydrochloride. No further information is available for evaluation.*
figure-3 - figure 3
figure-4 - figure 4
The figure 4 represents the mean change in IPSS Total Symptom Score in Trial 3 after 28 and 56 days of treatment with Aituzosin hydrochloride extended-release tablets compared to Placebo with a statistically significant difference (p<0.01) between the two groups.*
figure-5 - figure 5
The text provides statistical data related to the mean change from baseline in peak urine flow rate (mL/s) for a drug trial featuring a placebo group (N=167) and a group treated with alfuzosin hydrochloride extended-release tablets (N=170). The values are shown in a graph and there is a significant difference between the two groups. There is no additional information available.*
figure-6 - figure 6
This is a graph showing the mean change from baseline in peak urine flow rate in Trial 2. The graph shows results for individuals taking Atuzosin hydrochloride extended-release tablets compared to a placebo group. There were 136 participants in the Atuzosin group and 147 in the placebo group. The graph shows that there was a statistically significant improvement in peak urine flow rate in the Atuzosin group compared to the placebo group. Days of treatment are plotted on the x-axis, and peak urine flow rates in mL/s are plotted on the y-axis.*
figure-7 - figure 7
The text describes the results of a clinical trial (Trial 3) comparing the effects of a placebo (N=150) versus Alfuzosin hydrochloride extended-release tablets (N=151) on peak urine flow rate. The figure shows the mean change from baseline in peak urine flow rate (in mL/s) over a treatment period of 84 days. The statistical analysis indicated that there was no significant difference (NS) between the two treatments (p > 0.05).*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.